GRTS - Gritstone reaches six-month high on publication of data for cancer vaccine

• The shares of Gritstone bio, Inc. ( NASDAQ: GRTS ) climbed ~35% to reach the highest level since February on Tuesday after the clinical-stage biotech announced the publication of interim data from its Phase 1/2 trial for GRANITE, an individualized vaccine candidate for solid tumors.
• The data published in Nature Medicine on Monday were first shared at the European Society for Medical Oncology (ESMO) Congress 2021.
• According to detailed results, GRANITE led to robust tumor-specific CD4+ and CD8+ T cell responses that could potentially address various diseases.
• In addition, Gritstone ( GRTS ) said that colorectal cancer (CRC) patients who showed a molecular response during the study continued to improve in terms of overall survival compared to those who did not indicate a molecular reaction.
• The median overall survival of the group surpassed 18 months as of May 2022 compared to 7.8 months in those who did not indicate a molecular response.
• The data from the ongoing trial provided the foundation for two other trials for GRANITE, including a potentially pivotal Phase 2/3 trial involving certain patients with colorectal cancer.

For further details see: